Intellia Therapeutics financials
$12.03+5.34%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $67.7M | $57.9M | $36.3M | $52.1M | $33.1M | $58.0M | $43.1M | $30.4M | $26.1M | $16.5M |
| Gross profit | $67.7M | $57.9M | $36.3M | $52.1M | $33.1M | $58.0M | $43.1M | $30.4M | $26.1M | $16.5M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$441.0M | -$534.3M | -$515.3M | -$471.6M | -$267.9M | -$136.6M | -$106.4M | -$90.9M | -$69.6M | -$32.2M |
| Net income | -$412.7M | -$519.0M | -$481.2M | -$474.2M | -$267.9M | -$134.2M | -$99.5M | -$85.3M | -$67.5M | -$31.6M |
| Net margin | −609.9% | −896.8% | −1326.5% | −909.8% | −810.5% | −231.5% | −230.9% | −280.4% | −258.6% | −192.0% |
| Diluted EPS | $-3.81 | $-5.25 | $-5.42 | $-6.16 | $-3.78 | $-2.40 | $-2.11 | $-1.98 | $-1.88 | $-1.42 |
| EBITDA | -$431.2M | -$524.0M | -$506.3M | -$450.6M | -$261.0M | -$130.3M | -$100.8M | -$86.4M | -$66.6M | -$31.1M |
| Operating cash flow | -$394.7M | -$348.9M | -$394.1M | -$346.8M | -$225.0M | -$49.9M | -$103.2M | -$61.3M | -$65.3M | $35.5M |
| Free cash flow | -$395.9M | -$354.7M | -$408.1M | -$360.3M | -$237.8M | -$53.5M | -$110.0M | -$67.6M | -$75.4M | $29.3M |
| Diluted shares | 108.4M | 98.8M | 88.8M | 77.0M | 70.9M | 56.0M | 47.2M | 43.1M | 36.0M | 22.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $155.5M | $189.2M | $226.7M | $523.5M | $123.4M | $160.0M |
| Short-term investments | $294.4M | $412.3M | $685.5M | $669.1M | $625.3M | $437.4M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $842.1M | $1.19B | $1.30B | $1.52B | $1.29B | $676.3M |
| Total liabilities | $170.7M | $319.1M | $250.8M | $284.5M | $254.2M | $149.3M |
| Shareholders' equity | $671.4M | $872.0M | $1.05B | $1.24B | $1.04B | $527.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology